Paid Clinical Trials Paid Clinical Trials > Browse Categories > Medications / Interventions > Aa > Allopurinol

Allopurinol

Allopurinol

All Categories Medications / Interventions » Aa » Allopurinol


  • A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

    Condition:   Diabetic Nephropathies
    Interventions:   Drug: Allopurinol;   Drug: Placebo
    Sponsors:   Joslin Diabetes Center;   Alessandro Doria;   Steno Diabetes Center;   University of Michigan;   University of Minnesota - Clinical and Translational Science Institute
    Not yet recruiting - verified April 2012
  • Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

    Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Blastic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   de Novo Myelodysplastic Syndromes;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: rasburicase;   Drug: allopurinol;   Drug: rasburicase
    Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
    Recruiting - verified January 2012
  • Combining Lesinurad With Allopurinol in Inadequate Responders

    Condition:   Gout
    Interventions:   Drug: Lesinurad;   Drug: Lesinurad;   Drug: Placebo
    Sponsors:   Ardea Biosciences, Inc.;   Ardea Biosciences, Inc.
    Recruiting - verified May 2012
  • Combining Lesinurad With Allopurinol in Inadequate Responders

    Condition:   Gout
    Interventions:   Drug: Lesinurad;   Drug: Lesinurad;   Drug: Placebo
    Sponsors:   Ardea Biosciences, Inc.;   Ardea Biosciences, Inc.
    Recruiting - verified May 2012
  • T-Cell Depleted Double UCB for Refractory AML

    Conditions:   Acute Myelogenous Leukemia;   Refractory Acute Myelogenous Leukemia
    Interventions:   Drug: Allopurinol;   Drug: Fludarabine;   Radiation: Total body irradiation;   Drug: Cyclophosphamide;   Drug: Levetiracetam;   Drug: Busulfan;   Biological: Umbilical Cord Blood Transplantation;   Biological: Interleukin-2
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified November 2011
  • Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares

    Condition:   Gout
    Interventions:   Drug: Rilonacept;   Drug: Placebo;   Drug: Allopurinol
    Sponsors:   Regeneron Pharmaceuticals;   Regeneron Pharmaceuticals
    Recruiting - verified January 2012
  • Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol

    Condition:   Intercritical Gout
    Interventions:   Drug: Colchicine;   Drug: Placebo;   Drug: Allopurinol
    Sponsors:   Regeneron Pharmaceuticals;   Regeneron Pharmaceuticals
    Recruiting - verified April 2012
  • Allopurinol Outcome Study

    Condition:   Gout
    Intervention:   Drug: Allopurinol
    Sponsors:   Ardea Biosciences, Inc.;   Ardea Biosciences, Inc.
    Recruiting - verified May 2012
  • Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function

    Conditions:   Renal Function;   Endothelial Function;   Blood Pressure;   Overweight;   Obesity
    Interventions:   Drug: Vitamin D ergocalciferol;   Drug: Probenecid;   Drug: Allopurinol;   Drug: Placebo;   Drug: Placebo
    Sponsors:   Brigham and Women's Hospital;   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified January 2012
  • Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Drug: Rasburicase;   Drug: Allopurinol
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Sanofi-Aventis
    Recruiting - verified April 2012
  • Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

    Condition:   Cardiovascular Disease
    Interventions:   Drug: Febuxostat;   Drug: Allopurinol
    Sponsors:   Takeda Global Research & Development Center, Inc.;   Takeda Global Research & Development Center, Inc.
    Recruiting - verified February 2012
  • Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive

    Condition:   Severe Hemophilia A
    Interventions:   Drug: FVIII Concentrates;   Drug: FVIII/VWF concentrates
    Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   Grifols Biologicals Inc.;   CSL Behring;   Grifols Therapeutics Inc.;   Biotest Pharmaceuticals Corporation
    Recruiting - verified March 2012
  • Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels

    Conditions:   Heart Failure;   Elevated Serum Uric Acid
    Interventions:   Drug: allopurinol;   Drug: sugar pill
    Sponsors:   Duke University;   Duke University;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified April 2012
  • Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

    Conditions:   Leukemia;   Acute Lymphoblastic Leukemia
    Intervention:   Drug: Dasatinib, Mitoxantrone, Cytarabine
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Bristol-Myers Squibb
    Recruiting - verified January 2012
  • Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

    Condition:   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Lenalidomide;   Drug: Fludarabine;   Drug: Rituximab;   Drug: Thymoglobulin;   Procedure: Stem Cell Transplantation;   Drug: Bendamustine;   Drug: Allopurinol
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation
    Recruiting - verified May 2012
  • Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

    Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: stem cell transplantation;   Radiation: total-body irradiation;   Drug: methylprednisolone;   Drug: allopurinol;   Drug: filgrastim
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012

Main Menu
Clinical Trial Categories
Clinical Trial Locations